Zura Bio halted development of its experimental skin-disease drug after it missed the main goal in a mid-stage trial, sending shares down 75% in morning trading. The treatment failed to show a benefit over placebo in reducing abscesses and inflammatory skin nodules for patients with hidradenitis suppurativa after 16 weeks. Investors dumped the stock as the setback wiped out the primary catalyst for the company's dermatology pipeline.

Pipeline Pivot and Cash Runway